Bristol-Myers Squibb (BMY) PEG Ratio: History & Chart

Bristol-Myers Squibb Company(BMY)

Drug Manufacturers - General · Princeton, NJ

$64.69-2.13 (-3.19%)

At close: Sep 8, 2026 (market close, ET)

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher Boerner

View full financials

BMY PEG Ratio Metrics

PEG RATIO

1.52

PEG RATIO AVG TTM

0.24

PEG RATIO AVG 3Y

0.24

PEG RATIO AVG 5Y

0.18

PEG RATIO AVG 10Y

0.14

PEG RATIO AVG 15Y

0.32

PEG RATIO AVG 20Y

0.35

CURRENT VS TTM AVG

+520.41%

CURRENT VS 3Y AVG

+520.41%

CURRENT VS 5Y AVG

+744.44%

CURRENT VS 10Y AVG

+985.71%

CURRENT VS 15Y AVG

+375.00%

CURRENT VS 20Y AVG

+330.93%

SECTOR MEDIAN · HEALTHCARE

1.81

median of 59 covered companies

CURRENT VS SECTOR MEDIAN

-16.02%

vs the sector median at left

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Bristol-Myers Squibb Company (BMY)	$132.14B	1.52	0.24	0.24	0.18
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$134.24B	3.89	2.58	1.90	1.47
Intuitive Surgical, Inc. (ISRG)vs ›	$123.70B	3.17	3.02	2.60	2.27
CVS Health Corp. (CVS)vs ›	$122.58B	N/A	0.13	1.20	1.17
Danaher Corporation (DHR)vs ›	$144.25B	92.21	1.24	1.13	1.93
Medtronic plc (MDT)vs ›	$118.26B	6.72	3.73	3.73	2.72
Stryker Corporation (SYK)vs ›	$105.97B	5.16	5.16	2.81	2.63
Pfizer Inc. (PFE)vs ›	$158.39B	N/A	0.07	0.13	0.16
McKesson Corporation (MCK)vs ›	$104.10B	0.46	1.11	0.76	0.58
Sanofi (SNY)vs ›	$103.62B	0.28	5.85	4.07	3.06

NAME

MARKET CAP

PEG RATIO

TTM

Bristol-Myers Squibb Company (BMY)

$132.14B

1.52

0.24

0.18

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$134.24B

3.89

2.58

1.90

1.47

Intuitive Surgical, Inc. (ISRG)vs ›

$123.70B

3.17

3.02

2.60

2.27

CVS Health Corp. (CVS)vs ›

$122.58B

N/A

0.13

1.20

1.17

Danaher Corporation (DHR)vs ›

$144.25B

92.21

1.24

1.13

1.93

Medtronic plc (MDT)vs ›

$118.26B

6.72

3.73

2.72

Stryker Corporation (SYK)vs ›

$105.97B

5.16

2.81

2.63

Pfizer Inc. (PFE)vs ›

$158.39B

N/A

0.07

0.13

0.16

McKesson Corporation (MCK)vs ›

$104.10B

0.46

1.11

0.76

0.58

Sanofi (SNY)vs ›

$103.62B

0.28

5.85

4.07

3.06

PEG Ratio FAQ

What is the PEG ratio for Bristol-Myers Squibb Company (BMY)?

The PEG ratio for BMY stock is 1.52.

Is Bristol-Myers Squibb Company's PEG ratio high or low?

The PEG ratio of 1.52 is 744% above its 4-year average of 0.18, near the high end of its 4-year range (0.05–1.52).

What is the TTM average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The TTM average PEG ratio for BMY stock is 0.24.

What is the 3Y average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The 3Y average PEG ratio for BMY stock is 0.24.

What is the 5Y average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The 5Y average PEG ratio for BMY stock is 0.18.

What is the 10Y average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The 10Y average PEG ratio for BMY stock is 0.14.

What is the 15Y average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The 15Y average PEG ratio for BMY stock is 0.32.

What is the 20Y average PEG ratio for Bristol-Myers Squibb Company (BMY)?

The 20Y average PEG ratio for BMY stock is 0.35.

DATE	PEG RATIO
2024-12-31	0.06
2023-12-31	0.43
2020-12-31	0.05
2018-12-31	0.04
2016-12-31	0.12
2013-12-31	1.02
2011-12-31	0.79
2009-12-31	0.05
2008-12-31	0.06
2007-12-31	0.67
2005-12-31	0.59
2003-12-31	0.32
2001-12-31	1.51
2000-12-31	2.05
1999-12-31	0.88
1997-12-31	2.09
1996-12-31	0.32

DATE

PEG RATIO

2024-12-31

0.06

2023-12-31

0.43

2020-12-31

0.05

2018-12-31

0.04

2016-12-31

0.12

2013-12-31

1.02

2011-12-31

0.79

2009-12-31

0.05

2008-12-31

0.06

2007-12-31

0.67

2005-12-31

0.59

2003-12-31

0.32

2001-12-31

1.51

2000-12-31

2.05

1999-12-31

0.88

1997-12-31

2.09

1996-12-31

0.32

PEG Ratio: 1.52

BMY PEG Ratio Chart

BMY Average PEG Ratio Chart

BMY Current vs Average PEG Ratio Chart

BMY PEG Ratio Metrics

BMY Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

PEG Ratio FAQ

BMY PEG Ratio History

Related Metrics